Gilead Says Hepsera Will Benefit From New Competition In Hep B Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Chronic hepatitis B market will be expanded by competitors' disease-awareness campaigns, Gilead says. Bristol-Myers Squibb's Baraclude cleared FDA in March; Roche's Pegasys user fee deadline is in May.